Recursion Pharmaceuticals bounced back by 8.72 percent on Tuesday to close at $5.36 apiece following news that it acquired a $25-million interest in REV102—an ENPP1 inhibitor in preclinical ...

Recursion Pharmaceuticals dropped its share prices by 6.45 percent on Monday to close at $4.93 apiece as investors appeared to have booked profits following four straight days of gains. In recent ...

Recursion Pharmaceuticals continues to have a pipeline of drugs that might provide further validation for the company's platform. See why I rate RXRX a Sell.

Recursion Pharmaceuticals (RXRX) stock gains as the company plans a 20% workforce reduction to streamline operations and extend cash runway to Q4 2027. Read more here.

Recursion Pharmaceuticals said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding crunch and the current policy uncertainty.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading higher and trending. The company on Tuesday announced a reduction in personnel and infrastructure aimed at extending its cash runway.

Recursion Pharmaceuticals plans to slash one-fifth of its workforce as it looks to streamline its operations. The clinical-stage biopharmaceutical company said Tuesday it will reduce its workforce ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.

MIT and Recursion partner for AI drug discovery tool Freely available Boltz-2 algorithm can predict small-molecule binding affinities by Laura Howes ...

Recursion shares jumped over 18% after launching Boltz-2, a breakthrough AI model with MIT that predicts molecular binding The open-source model significantly accelerates drug discovery, making ...

Best known for the Recursion Studio, Entropy & Sons crafts devices that allow users to generate high-definition, real-time visual compositions without a computer.